Asco 2023 – Novocure sinks as Lunar’s limitations become clear
A pivotal lung cancer hit in an outdated setting means the company might struggle with adoption.
Novocure aims to plough a new field
Lung cancer approval for the group’s electric fields-based therapy could come this year, but Novocure has broader solid tumour ambitions.
Diabetes device makers lead the smaller medtechs
Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.
Telemedicine and the “Zoom effect” boost big-cap medtech
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
Smaller device makers put in a muted performance
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.